Furthermore, a prospective and randomized study showed that EBR/GZR ± RBV was highly efficacious in inducing SVR12 in patients with HCV GT 1, 4, or 6 infection which failed on previous treatment with peg-interferon and RBV, PI-based combination regimens, NS3 RAVs, and cirrhosis and/or a prior null response (Buti et al., 2016; Kwo et al., 2017). The gene discussed is KRAS; the disease is Cirrhosis.